HIV

GSK posts data on HIV assets vying for roles in 6-month combo

GSK shared clinical data on three potential long-acting HIV therapies, providing a look at how its plans to create a six-month regimen are shaping up.

Nick Paul Taylor Mar 12, 2025 11:25am

Immunocore bispecific reduces HIV reservoir in early trial

Mar 10, 2025 3:00pm

Merck's HIV combo treatment meets efficacy bar in phase 3 trials

Dec 19, 2024 11:54am

Jury convicts 2 former biopharma leaders of fraud

Dec 11, 2024 10:26am

Gilead buys HIV vaccine from biotech following clinical collab

Nov 25, 2024 10:30am

Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks

Oct 21, 2024 5:06am